Phio Pharmaceuticals Corp.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $0
- Net income
- -$8.7M
- Total assets
- $21.5M
- Market cap
- $12.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $9.2M
- Operating income
- -$9.2M
- Income tax
- $0
- Net income
- -$8.7M
- EPS (basic)
- $-1.45
Balance sheet
- Total assets
- $21.5M
- Current assets
- $21.5M
- Total liabilities
- $1.3M
- Current liabilities
- $1.3M
- Shareholders’ equity
- $20.1M
Cash flow
- Operating cash flow
- -$8.0M
- Investing cash flow
- -$12.0K
- Financing cash flow
- $23.6M
- Net cash flow
- $15.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.3M
- Shares outstanding
- 11.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 10, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.7M in FY2020.
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Phio Pharmaceuticals Corp..
Write a review
News about Phio Pharmaceuticals Corp.
News & sentiment via Polygon.io
